SCHEMBL6804222

SCHEMBL6804222

CC1CCCN(C(C)NC(=S)Nc2ccc(Br)cn2)C1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
POLB P06746 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
HCRTR2 O43614 3/20 0.38
HCRTR1 O43613 2/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
LTC4S Q16873 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6804427 0.87 RAB9A (0.44) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL7579004 0.86 ALDH1A1 (0.49) ALDH1A1POLBSMN1; SMN2RAB9ANPC1
SCHEMBL6229771 0.85 ALDH1A1 (0.48) ALDH1A1POLBSMN1; SMN2RAB9ANPC1
SCHEMBL6805540 0.80 ALDH1A1 (0.45) ALDH1A1POLBSMN1; SMN2HCRTR2HCRTR1
SCHEMBL8197938 0.79 TSHR (0.52) ALDH1A1POLBSMN1; SMN2RAB9ANPC1
SCHEMBL6804219 0.76 POLB (0.43) ALDH1A1POLBSMN1; SMN2HCRTR2HCRTR1
SCHEMBL7097157 0.76 ALDH1A1 (0.53) ALDH1A1POLBSMN1; SMN2RAB9ANPC1
SCHEMBL30557772 0.74 ALDH1A1 (0.48) ALDH1A1POLBSMN1; SMN2RAB9ANPC1
SCHEMBL6805138 0.71 RAB9A (0.50) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL29806039 0.67 L3MBTL1 (0.51) SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689793-B2 INHIBITORS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE AND MULTI-DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS REVERSE TRANSCRIPTASE PARKER HUGHES INSTITUTE 2004-02-10 US claimed
US-20020151568-A1 Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity PARKER HUGHES INSTITUTE 2002-10-17 US claimed
US-6689793-B2 INHIBITORS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE AND MULTI-DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS REVERSE TRANSCRIPTASE PARKER HUGHES INSTITUTE 2004-02-10 US disclosed
US-20020151568-A1 Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity PARKER HUGHES INSTITUTE 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151568-A1 Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity SAMHD1, PNP, NUDT1 ALDH1A1 1567/4885POLB 77/4885SMN1; SMN2 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.